ArticleHeart rhythm O22026
Pulmonary vein isolation and beyond: Feasibility and acute outcomes of the lattice-tip dual-energy catheter for complex ablations.
Article in Heart rhythm O2, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05521451 (Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Longterm Outcome and Predictors for Recurrence After Medical and Interventional Treatment of Arrhythmias At the University Heart Center Hamburg
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A new large-footprint catheter that switches between pulsed field ablation (PFA) and radiofrequency ablation (RFA) and integrates with a novel 3-dimensional (3D) mapping platform has been introduced. Objective: This study aimed to evaluate the safety, efficacy, and procedural characteristics of the large-footprint dual-energy catheter in patients undergoing catheter ablation for atrial fibrillation or atrial tachycardia. Methods: Consecutive patients undergoing left (LA) and right atrial ablation for atrial fibrillation or atrial tachycardias were analyzed. All patients were enrolled in the prospective TRUST Registry (NCT05521451). Results: 102 patients (37 women [36%]; median age 68 years [60-75]; median left ventricular ejection fraction 60% [53-60]) were included; 42 (41%) underwent first pulmonary vein isolation (PVI), and 57 (56%) repeat PVI. Median procedure and mapping times were 91 minutes (78-114) and 15 minutes (11.9-21.7), respectively; median 3D LA volume was 165 mL (142-199).In 75 patients (42 index, 33 repeat procedures), pulmonary veins were targeted, and first-pass isolation was achieved in all using PFA only (median ablation 25 minutes [16-34]). Additional LA lines were applied in 87 of 102 (85%): anterior (34, 25 of 34 [73%] PFA + RFA), mitral isthmus (27, 18 of 27 [67%] PFA + RFA; 5 of 27 [18%] with PFA in the coronary sinus), posterior box (45, PFA only), and roof (23, PFA only). All lines were bidirectionally blocked, and posterior boxes isolated. A cavotricuspid isthmus line was created in 36 of 102 (35%; 30 of 36 [83%] RFA only). Procedural complications occurred in 3 of 102 (2.9%). Conclusion: The large-footprint dual-energy catheter enables safe and effective PVI, repeat PVI, and creation of complex left and right atrial lesion sets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.